Skip to main content
. 2021 May 21;75(7):227–235. doi: 10.1111/pcn.13221

Fig. 2.

Fig. 2

Change from baseline in (a) Positive and Negative Syndrome Scale (PANSS) total score, (b) Clinical Global Impression‐Severity Scale (CGI‐S) score in the intent‐to‐treat (ITT) population (n = 478). (Inline graphic) Placebo. (Inline graphic) Lurasidone. *P < 0.05, **P < 0.01, ***P < 0.001 vs placebo. Data represent least squares mean estimate ± standard errors. MMRM, mixed model for repeated measures.